HCPLive Network

Kynamro Approved for Genetic Condition Tied to Cholesterol

 
WEDNESDAY, Jan. 30 (HealthDay News) -- Kynamro (mipomersen sodium) has been approved by the U.S. Food and Drug Administration to treat homozygous familial hypercholesterolemia (HoFH), a rare inherited condition in which the body can't remove low-density lipoprotein (LDL) cholesterol from the blood, as an addition to lipid-lowering medications and diet.

Many people with HoFH have a heart attack and die before age 30, the FDA said in a news release. HoFH affects approximately one in every one million people in the United States. Kynamro is a once-weekly injection designed to lower creation of blood lipid particles that ultimately form LDL, the agency said.

The drug was clinically evaluated among 51 people with HoFH. Among Kynamro users, LDL levels fell an average of about 25 percent during the first 26 weeks, the FDA said. The drug will carry a "black box" label warning of possible liver abnormalities that could lead to progressive liver disease.

More common side effects noted during clinical testing included injection-site reactions, flu-like symptoms, nausea, headache, and elevated liver enzymes.

Kynamro is produced by Genzyme Corp., of Cambridge, Mass.
 

More Information


Copyright © 2013 HealthDay. All rights reserved.
 
 

Further Reading
Around 10% of elders experience some form of elder abuse (physical, sexual or emotional abuse; neglect, exploitation, or abandonment), and elders who are abused appear to have a high level of comorbidity. Evidence suggests that patients who have experienced elder abuse are at higher risk of cardiovascular-related mortality.
This 71 year old woman presented with an itchy raised erythematous leg lesion that had been present for 10 months. She has a history of significant sun exposure in the past and was prescribed topical triamcinolone 4 months ago which she believes has made it slightly smaller and less itchy.
This cohort study looked at the influence of maintaining a Mediterranean diet on telomere length, which is commonly used as a surrogate marker for longevity.
More Reading